查看文章

ChAdOx1 nCOV-19 (Vaxzevria) is a vaccine against SARS-CoV-2 infection (COVID-19) developed by Oxford University and AstraZeneca that uses a replication-deficient chimpanzee adenoviral vector (ChAdOx1) containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene1. Over the last few weeks, there have been several reports of thromboembolic events in subjects who had been administered Vaxzevria in the previous weeks. This led several European countries to decide to suspend its administration or, more recently, to limit it to subjects over 60 years of age2, 3.

While the incidence of venous thromboembolism (VTE) at usual sites in vaccinated subjects has not exceeded that in the non-vaccinated population4, 5, a rare and particular type of event has been described following vaccination. This is characterised by cerebral and/or splanchnic vein thrombosis, often …